Dr. John E. Call, MD

Dr. Call practices at The Tresanti Surgical Center in San Ramon, California.

Dr. Call's NPI, 1376997767, was assigned on April 21, 2016. Dr. Call graduated from Texas A&M College of Medicine - Bryan in 2016. Dr. Call holds California license A169621.

Dr. Call's primary practice is The Tresanti Surgical Center, at 5201 Norris Canyon Road, Suite 100, San Ramon, CA 94583. The practice phone is (925) 937-0605.

Dr. Call's primary practice is The Tresanti Surgical Center in San Ramon, California. Dr. Call is also affiliated with Stanford Health Care Tri-Valley. The medical group on file is Golden State Dermatology. Dmand AI also links Dr. Call to 2 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Call practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Call's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Call is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Call's licenses on file in 2 states: California and New Hampshire.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, corns and calluses and facial skin infection among the conditions Dr. Call treats.

CMS data shows 14,139 Medicare services from Dr. Call across 33 procedure codes in 2024, for 1,253 Medicare patients. Medicare paid $1,107,325 for them. Every service was in an office.

CMS counts 1,253 Medicare patients who saw Dr. Call in 2026. The largest group is 65 to 74, with 567 patients. 75% of them have high cholesterol, and 65% have high blood pressure. 4% are also on Medicaid. Their average risk score is 0.92, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Call's median patient age at 59, with 49% women.

In 2026, Dr. Call wrote 1,433 Medicare Part D claims for 549 patients. 92% of them were for generic drugs. CMS names the drug for 1,271 of them, across 31 drugs with 11 or more claims each, at $254,200 in total drug cost. In 2023, CMS named 1,063 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Call for performance year 2026, reported as part of a group. Dr. Call accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 2,944 procedures of removal of skin lesions by Dr. Call, more than 99% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 4 papers to Dr. Call, published from 2018 to 2020. Dr. Call's most frequent co-authors are Stephanie Andrea Castillo, MD, Michael Shane Chapman, MD and Jonathan Saul Glass, MD.

CMS Open Payments shows 738 general payments to Dr. Call from 31 drug and device companies from 2019 to 2025. Speaker and faculty fees make up the largest share, 68% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $29,690.

Dr. Call graduated from Texas A&M College of Medicine - Bryan in 2016.

Dr. Call is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.